Literature DB >> 2644108

Single-dose cefotetan vs. multiple-dose cefoxitin--antimicrobial prophylaxis in colorectal surgery. Results of a prospective, multicenter, randomized study.

P Periti1, T Mazzei, F Tonelli.   

Abstract

This multicenter, prospective, randomized trial of short-term antimicrobial prophylaxis in colorectal surgery was designed to compare the efficacy of a single dose of cefotetan vs. multiple doses of cefoxitin. Of the 403 evaluable patients, 206 received cefoxitin (1 gm intravenously at the beginning of surgery and after 3, 6, and 12 hours, group A) and 197 cefotetan (2 gm intravenously at the beginning of surgery, group B). The two groups of patients were similar in respect to age, sex, obesity, preoperative weight loss, diabetes, type of disease, type, and mean duration of surgery. The abdominal wound infection rate was 11.2 percent in group A and 9.1 percent in group B (difference not significant). The number of patients with infections at nonsurgical sites (respiratory and urinary tract, phlebitis, and septicemia) was significantly greater in group A than in group B (17 vs. 9.1 percent, P less than .05). The mean postoperative hospital stay was similar in both the cefoxitin and cefotetan groups (15.1 vs. 15.9 days). Both regimens were inadequate in preventing infections in the presence of severe contamination of the operative field.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644108     DOI: 10.1007/bf02553824

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

1.  Septic complications of elective laparoscopic colorectal resection.

Authors:  E C Poulin; C M Schlachta; P A Seshadri; M O Cadeddu; R Grégoire; J Mamazza
Journal:  Surg Endosc       Date:  2001-02       Impact factor: 4.584

2.  Cefotetan versus conventional triple antibiotic prophylaxis in elective colorectal cancer surgery.

Authors:  Woon Kyung Jeong; Ji Won Park; Seok-Byung Lim; Hyo Seong Choi; Seung-Yong Jeong
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

3.  Serum in vivo and in vitro activity of single dose of ertapenem in surgical obese patients for prevention of SSIs.

Authors:  Carlo de Werra; Rosa Di Micco; Vincenzo Pilone; Antonio Formato; Emma Montella; Antonietta Lambiase; Domenica Cerbone; Maria Rosaria Catania; Pietro Forestieri
Journal:  Obes Surg       Date:  2013-07       Impact factor: 4.129

4.  Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors:  M J Gribble
Journal:  CMAJ       Date:  1994-09-01       Impact factor: 8.262

5.  Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.

Authors:  Fausto de Lalla
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.